Contraindications to the use of metformin.

Reports that metformin may reduce cardiovascular risks in patients with type 2 diabetes. Discussion of a United Kingdom diabetes study indicating metformin produced similar degrees of glycemic control and significantly reduced microvascular end points as did sulphonylurea and insulin; Results indicating that group tested with metformin had no hypoglycemia and less weight gain than groups tested with sulphonylurea and insulin; How metformin reduced the risk in mortality, diabetes-related deaths and diabetes-related end points.